Loading...
Women receiving endocrine therapy for the treatment or prevention of breast cancer commonly report vasomotor symptoms. Current treatments (gabapentin, low-dose antidepressants, acupuncture, lifestyle interventions, and complementary products like black cohosh) have not been very effective. In an industry-supported, phase 3 study, Cardoso et al. examined the effectiveness of the investigational drug elinzanetant in 474 women with moderate-to-severe vasomotor symptoms who were receiving endocrine therapy to treat or prevent breast cancer. Elinzanetant is a neurokinin (NK)-targeted therapy that specifically antagonizes NK-1 and NK-3 receptors, which are implicated in declining estrogenic activity that occurs with natural menopause or antiestro…